- Previous Close
46.42 - Open
46.47 - Bid 45.39 x 100
- Ask 47.38 x 100
- Day's Range
46.47 - 46.72 - 52 Week Range
39.12 - 63.00 - Volume
1,675 - Avg. Volume
414,303 - Market Cap (intraday)
2.342B - Beta (5Y Monthly) 1.79
- PE Ratio (TTM)
233.60 - EPS (TTM)
0.20 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
65.38
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
www.vcel.comRecent News: VCEL
View More
Performance Overview: VCEL
Trailing total returns as of 3/27/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VCEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VCEL
View MoreValuation Measures
Market Cap
2.33B
Enterprise Value
2.31B
Trailing P/E
232.10
Forward P/E
128.21
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.11
Price/Book (mrq)
7.97
Enterprise Value/Revenue
9.74
Enterprise Value/EBITDA
138.92
Financial Highlights
Profitability and Income Statement
Profit Margin
4.37%
Return on Assets (ttm)
0.72%
Return on Equity (ttm)
4.00%
Revenue (ttm)
237.22M
Net Income Avi to Common (ttm)
10.36M
Diluted EPS (ttm)
0.20
Balance Sheet and Cash Flow
Total Cash (mrq)
116.21M
Total Debt/Equity (mrq)
34.09%
Levered Free Cash Flow (ttm)
-11.76M
Research Analysis: VCEL
View MoreCompany Insights: VCEL
VCEL does not have Company Insights
Research Reports: VCEL
View MoreRaising target price to $50.00
VERICEL CORP has an Investment Rating of HOLD; a target price of $50.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLowering target price to $49.00
VERICEL CORP has an Investment Rating of HOLD; a target price of $49.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLowering target price to $51.00
VERICEL CORP has an Investment Rating of HOLD; a target price of $51.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $54.00
VERICEL CORP has an Investment Rating of HOLD; a target price of $54.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target